Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension
Journal of Neuromuscular Diseases · 2025-03 · 12 (2) · 231-243
DOI: 10.1177/22143602241308181 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 04.03.2025. Verfasst von Ali A Habib und 13 weiteren Autor:innen. Beteiligte Einrichtung: MDA ALS and Neuromuscular Center, Department of Neurology, University of California, Irvine, Orange, CA, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Myasthenia Gravis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Generalized myasthenia gravis (gMG) is a rare, chronic, fluctuating and heterogeneous autoimmune disease requiring lifelong treatment. The Phase 3 MycarinG study demonstrated the efficacy and safety of one 6-week cycle of weekly rozanolixizumab in adult patients with gMG. Open-label extension studies demonstrated consistent symptom improvement over additional treatment cycles.
Objective
To present findings from pooled analyses on the long-term safety of repeated cycles of rozanolixizumab.
Methods
Data from the Phase 3 randomized MycarinG study (NCT03971422) and the ongoing open-label extension study MG0007 (NCT04650854) were pooled to assess safety outcomes during cyclical treatment, including incidence of any treatment-emergent adverse events (TEAEs), severe TEAEs, serious TEAEs and TEAEs leading to discontinuations. Additional analyses were performed for TEAEs, including headache, infections, and hypersensitivity reactions.
Results
At data cutoff (July 8, 2022), a total of 188 patients in MycarinG and MG0007 had received ≥1 treatment cycle with rozanolixizumab; total time in studies was 174.71 patient-years. Overall, 169/188 (89.9%) patients experienced any TEAE: 89/188 (47.3%) experienced any headache (including migraine, migraine with aura); 85/188 (45.2%) experienced an infection; 25/188 (13.3%) experienced a hypersensitivity reaction. One patient experienced an event of aseptic meningitis. The majority of AEs were mild-to-moderate in intensity, and incidence did not increase with repeated cyclic treatment. A total of 50/188 (26.6%) patients experienced severe TEAEs, the most common of which were MG worsening in 4/133 (3.0%) and 7/131 (5.3%) patients in the rozanolixizumab 7 mg/kg and rozanolixizumab 10 mg/kg groups, respectively, MG crisis in 0 and 4/131 (3.1%) patients, and headache in 1/133 (0.8%) and 7/131 (5.3%) patients.
Conclusions
These pooled results, representing 174.71 patient-years in the studies, demonstrate that treatment with rozanolixizumab in patients with gMG was well tolerated, and TEAEs were consistent and did not increase in incidence over repeated cycles in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MDA ALS and Neuromuscular Center, Department of Neurology, University of California, Irvine, Orange, CA, USA.
- Department of Neurology, Municipal Hospital Poznań, Poznań, Poland.
- Precision Neurology of Neuromuscular Diseases, Department of Neurology, University of Lübeck, Lübeck, Germany.
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy.
- Université Côte d'Azur, Peripheral Nervous System and Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France.
- Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
Zitieren
APA
Habib, A. A., Drużdż, A., Grosskreutz, J., Mantegazza, R., Sacconi, S., Utsugisawa, K., Vu, T., Vissing, J., Gayfieva, M., Pulido-Valdeolivas, I., Tarancón, T., Woltering, F., Bril, V., & MycarinG and MG0007 study investigators (2025). Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. Journal of Neuromuscular Diseases, 12(2), 231-243. https://doi.org/10.1177/22143602241308181
Vancouver
Habib AA, Drużdż A, Grosskreutz J, Mantegazza R, Sacconi S, Utsugisawa K, et al. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. Journal of Neuromuscular Diseases. 2025;12(2):231-243. doi:10.1177/22143602241308181
BibTeX
@article{Habib2025,
author = {Habib, Ali A and Drużdż, Artur and Grosskreutz, Julian and Mantegazza, Renato and Sacconi, Sabrina and Utsugisawa, Kimiaki and Vu, Tuan and Vissing, John and Gayfieva, Maryam and Pulido-Valdeolivas, Irene and Tarancón, Thaïs and Woltering, Franz and Bril, Vera and MycarinG and MG0007 study investigators, MycarinG and MG0007 study investigators},
title = {Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension},
journal = {Journal of Neuromuscular Diseases},
year = {2025},
volume = {12},
number = {2},
pages = {231--243},
doi = {10.1177/22143602241308181}
}
EUVIMED